Practice Resources
AML and MDS resources and support for practices
Helpful practice resources and billing codes
Nurse and Pharmacist Guide
Download this guide featuring dosing guidance, side effect management, diagnosis codes, and specialty distributors.
Co-Pay Brochure
Download this brochure featuring eligibility criteria and enrollment details for the Taiho Oncology Co-Pay Assistance Program.
INQOVI Patient Welcome Kit
To help your patients start and stay on INQOVI, the kit includes content such as:
Patient and Caregiver Brochure
Important information on INQOVI for patients and caregivers, including dosing guidance, side effect management, and financial support
Health Journal
A journal of treatment and side effect trackers that help patients record their doses and report their side effects
Blister Pack Opener
A simple tool designed to help patients safely and easily open INQOVI blister packs
Codes relating to the use of INQOVI
The diagnostic codes contained in this section are designed to provide important reimbursement information that will be helpful for your pharmacy when ordering INQOVI. ICD codes continually change, so it is recommended that you consult your ICD-10 code book or contact the payer for coding and billing guidance.
Diagnosis codes for acute myeloid leukemia (AML)
| ICD‑10‑CM | Description |
|---|---|
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.60 | Acute myeloid leukemia with 11q23-abnormality not having achieved remission |
| C92.61 | Acute myeloid leukemia with 11q23-abnormality in remission |
| C92.62 | Acute myeloid leukemia with 11q23-abnormality in relapse |
| C92.A0 | Acute myeloid leukemia with multilineage dysplasia |
| C92.A1 | Acute myeloid leukemia with multilineage dysplasia, not having achieved remission |
| C92.A2 | Acute myeloid leukemia with multilineage dysplasia, in remission |
| C92.Z0 | Other myeloid leukemia, not having achieved remission (for other specific subtypes) |
AAPC. ICD-10-CM Expert 2025 for Providers & Facilities. American Academy of Professional Coders; 2025. This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring all coding is accurate and appropriate.
Formulation codes
| Formulation | Packaging | NDC (11-digit format)* |
|---|---|---|
| 35-mg decitabine and 100-mg cedazuridine | 5-tablet blister pack | 64842-0727-09 |
*The National Drug Code (NDC) has been “zero-filled” to convert the 10-digit NDC to an 11-digit NDC that meets Centers for Medicare & Medicaid Services standards. The zero-fill location is indicated in bold. Check payer requirements for appropriate reporting of the NDC.
Diagnosis codes for myelodysplastic syndromes (MDS)
| ICD‑10‑CM | Description |
|---|---|
| D46.0 |
Refractory anemia without ring sideroblasts, so stated Refractory anemia without sideroblasts, without excess of blasts |
| D46.1 | Refractory anemia with ring sideroblasts (RARS) |
| D46.2 | Refractory anemia with excess of blasts (RAEB) |
| D46.20 | Refractory anemia with excess of blasts, unspecified (RAEB NOS) |
| D46.21 | Refractory anemia with excess of blasts 1 (RAEB 1) |
| D46.22 | Refractory anemia with excess of blasts 2 (RAEB 2) |
| D46.A | Refractory cytopenia with multilineage dysplasia |
| D46.B | Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD RS) |
| D46.C |
Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality Myelodysplastic syndrome with 5q deletion 5q minus syndrome NOS |
| D46.4 | Refractory anemia, unspecified |
| D46.Z | Other myelodysplastic syndromes (EXCLUDES chronic myelomonocytic leukemia [C93.1]) |
| D46.9 |
Myelodysplastic syndrome, unspecified Myelodysplasia NOS |
AAPC. ICD-10-CM Expert 2020 for Providers & Facilities. American Academy of Professional Coders; 2020:505. This information is not intended as coverage or coding advice and does not guarantee reimbursement. You should verify the appropriate reimbursement information for services or items you provide. Each healthcare professional is responsible for ensuring all coding is accurate and appropriate.
Diagnosis codes for chronic myelomonocytic leukemia (CMML)
| ICD‑10‑CM | Description |
|---|---|
| C93.1 |
Chronic myelomonocytic leukemia Chronic monocytic leukemia CMML-1 CMML-2 CMML with eosinophilia |
| C93.10 |
Chronic myelomonocytic leukemia not having achieved remission Chronic myelomonocytic leukemia with failed remission Chronic myelomonocytic leukemia NOS |
| C93.11 | Chronic myelomonocytic leukemia, in remission |
| C93.12 | Chronic myelomonocytic leukemia, in relapse |
AAPC. ICD-10-CM Expert 2020 for Providers & Facilities. American Academy of Professional Coders; 2020:494.
Coding and Ordering Guide
Download this guide featuring diagnostic codes for MDS, diagnostic codes for CMML, and contact information for specialty distributors authorized to supply INQOVI to your on-site dispensing practice and specialty pharmacies authorized to dispense INQOVI to your patients.
Formulation codes
| FORMULATION | PACKAGING | NDC (11-DIGIT FORMAT)* |
|---|---|---|
| 35-mg decitabine and 100-mg cedazuridine | 5-tablet blister pack | 64842-0727-09 |
*The National Drug Code (NDC) has been “zero-filled” to convert the 10-digit NDC to an 11-digit NDC that meets Centers for Medicare & Medicaid Services standards. The zero-fill location is indicated in bold. Check payer requirements for appropriate reporting of the NDC.
Panel discussion video on MDS
Watch a hematologist-oncologist, nurse practitioner, and patient caregiver discuss treatment options, including INQOVI, for high-risk MDS.
